Robert Califf (Pablo Martinez Monsivais, AP Images, File)
November 12, 2021 10:06 AM ESTUpdated November 13, 02:58 AM
People
FDA+

It’s Califf: Biden picks the for­mer FDA com­mish to head back to the helm

Amber Tong

Senior Editor

Con­firm­ing one of the worst kept se­crets in Wash­ing­ton, Robert Califf has been nom­i­nat­ed on Fri­day to lead the FDA for a sec­ond time.

It’s an an­nounce­ment bio­phar­ma has anx­ious­ly been wait­ing for, al­though not a sur­pris­ing one. Af­ter vet­ting mul­ti­ple names churned out by the ru­mor mills, Pres­i­dent Joe Biden’s fi­nal choice is one both the in­dus­try and agency in­sid­ers have hailed as the per­fect one.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ab­b­Vie makes sec­ond deal in a week, bet­ting $8.7B in cash on CNS biotech Cerev­el 

Pfiz­er plans to pull out of BIO, fol­low­ing moves by oth­er large drug­mak­ers to re­duce lob­by­ing foot­print

Aviv Regev leads Genen­tech's next rev­o­lu­tion with AI

FDA ap­proves No­var­tis drug for rare blood dis­or­der

FDA sends let­ter to No­var­tis over Kym­ri­ah man­u­fac­tur­ing safe­ty con­cerns

sponsored

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

A service from the Financial Times